ALPHAMAB ONCOLOGY |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.75 HKD | +1.71% |
|
+13.91% | -28.46% |
| Sales 2023 | 219M 30.21M 236M 0 | Sales 2024 * | 246M 34M 266M 0 | Capitalization | 4.17B 576M 4.51B 0 |
|---|---|---|---|---|---|
| Net income 2023 | -211M -29.13M -228M - | Net income 2024 * | -299M -41.28M -323M - | EV / Sales 2023 | 22.8 x |
| Net cash position 2023 | 829M 114M 895M 0 | Net cash position 2024 * | 549M 75.78M 593M 0 | EV / Sales 2024 * | 14.7 x |
| P/E ratio 2023 |
-27.4
x | P/E ratio 2024 * |
-14
x | Employees | 435 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 49.21% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +1.71% | ||
| 1 week | +13.91% | ||
| Current month | +4.86% | ||
| 1 month | +9.45% | ||
| 3 months | +13.10% | ||
| 6 months | -59.33% | ||
| Current year | -28.46% |
1 week
4.21
4.84
1 month
4.014.85
Current year
3.816.71
1 year
3.8115.78
3 years
3.8128.70
5 years
3.8128.70
10 years
3.8128.70
| Managers | Title | Age | Since |
|---|---|---|---|
Ting Xu
CEO | Chief Executive Officer | 51 | 31/10/08 |
Jing Han
CMP | Compliance Officer | 51 | 01/11/21 |
Jinbo Wang
CTO | Chief Tech/Sci/R&D Officer | 50 | 18/03/18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Cheng Wei
BRD | Director/Board Member | 56 | 23/11/19 |
Ting Xu
CEO | Chief Executive Officer | 51 | 31/10/08 |
Yang Liu
COO | Chief Operating Officer | 52 | 30/09/18 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.21% | 4 M€ | -27.92% | ||
| 0.06% | 2 M€ | -14.14% | ||
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 117 M€ | +1.11% | - | |
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 4.75 | +1.71% | 1 622 500 |
| 26/04/24 | 4.67 | +4.94% | 2,219,500 |
| 25/04/24 | 4.45 | +0.91% | 1,621,300 |
| 24/04/24 | 4.41 | +1.38% | 1,335,500 |
| 23/04/24 | 4.35 | +4.32% | 2,728,000 |
Delayed Quote Hong Kong S.E., April 29, 2024 at 06:55 am
More quotes
Alphamab Oncology is an investment holding company primarily engaged in the biopharmaceutical business. The Company is a full-industry chain enterprise specializing in research, development, manufacture, and commercialization of innovative tumor immunobiology macromolecular targeted drugs. The Company has bio-innovation drug development technology platform, including protein engineering platform, multi-functional antibody development platform and antibody screening platform. The Company operates its businesses in both domestic and overseas markets.
Calendar
12/06/2024
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
4.323
CNY
Average target price
4.211
CNY
Spread / Average Target
-2.58%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -28.46% | 576M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- 9966 Stock
